Junion

Junion Therapeutics was founded in Singapore in 2020 by medical materials experts from the National University of Singapore and Nanyang Technological University. Today, it has brought together dozens of top-tier professionals from Singapore, China, the United States, and other regions worldwide. The company focuses on fundamental research and process innovation in biomedical polymer materials, and, through its patented drug-device combination technologies, is reshaping existing treatment paradigms for chronic diseases. With a strong emphasis on major chronic diseases with unmet clinical needs—including obesity, diabetes, neurological disorders, and cardiovascular diseases—Junion integrates cutting-edge advancements across pharmacy, materials science, biology, and engineering to develop transformative pharmaceutical products and therapies. Aspiring to become a high-tech enterprise that unites research, development, production, and commercialization, the company advances R&D through its “discipline integration – technology platforms – patented products” model. To date, Junion Therapeutics has established multiple technology platforms and has deployed innovative products across Singapore, China, the United States, and beyond.